Scarica l'app Stockscreener
3.13
1.95%
0.06
Quantum Biopharma Ltd Borsa (QNTM) Ultime notizie
Quantum Biopharma Provides Corporate Update - The Manila Times
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Myelin-Protecting MS Therapy as Treatment Paradigm Evolves - TradingView
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Myelin-Protecting MS Therapy as Treatment Paradigm - Benzinga
Quantum BioPharma Stock Gains 6.7% on FDA Clearance for Lucid-MS Phase 2 Trial - kalkine.ca
Quantum BioPharma Stock Under Pressure as Regulatory Uncertainty Tests the Lucid-MS Growth Story - kalkine.ca
Quantum BioPharma Stock Slides as Bearish Momentum, Funding Risk and Biotech Volatility Pressure CN:QNTM - kalkine.ca
Quantum (QNTM) Results Breakdown: The Latest Report Adds New Financial Reference Points under the Current Snapshot; Post-Earnings Trading: The Stock Records a 9.24% Decrease on the DayGuidance Revision Trend - vinanet.vn
Quantum BioPharma Ltd. (NASDAQ: QNTM) Share Price, QNTM Stock News, QNTM Share Price & Updates - Kalkine
Quantum BioPharma (QNTM) Reports Lower Q2 Expenses, Advances Lucid-MS Into Phase 2 - NewMediaWire
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Reports Lower Q2 Expenses, Advances Lucid-MS Into Phase 2 - Benzinga
Quantum BioPharma Ltd (CN:QNTM) Gains Momentum as Clinical Breakthroughs Improve Investor Outlook - kalkine.ca
Quantum BioPharma Ltd Stock Intrinsic Values | HAM:0K91 - GuruFocus
Quantum BioPharma Ltd Stock Historical Valuations - GuruFocus
QNTM Q4 2025 Earnings: Loss of $0.71 Per Share Reported as Stock Advances 17.65%Revenue Report - Vinanet
Quantum BioPharma Ltd (HAM:0K91) Stock Earnings Transcripts - GuruFocus
Quantum BioPharma Ltd (HAM:0K91) Stock Price, Trades & News - GuruFocus
Who's Buying or Selling Quantum BioPharma Ltd (HAM:0K91) Stock Today? - GuruFocus
Quantum BioPharma (HAM:0K91) ROC (Joel Greenblatt) % : -34,873.53% (As of Mar. 2026) - GuruFocus
HAM:0K91 Dividend: Does Quantum BioPharma Ltd Pay a Dividend? - GuruFocus
Quantum BioPharma Ltd (HAM:0K91) Stock Price & 30 Year Financial Data - GuruFocus
Quantum BioPharma Ltd Stock Operating Data - GuruFocus
Quantum BioPharma Ltd (HAM:0K91) Competitors 2026 - GuruFocus
Quantum BioPharma Ltd (HAM:0K91)Valuation Measures & Financial Statistics - GuruFocus
Quantum BioPharma Ltd (HAM:0K91) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Quantum BioPharma Ltd (HAM:0K91) Valuation - GuruFocus
Quantum BioPharma Ltd (HAM:0K91) Stock News, Headlines & Updates - GuruFocus
Quantum BioPharma (HAM:0K91) EPS (Basic) : €-7.12 (TTM As of Mar. 2026) - GuruFocus
Quantum BioPharma (HAM:0K91) Dividend Yield % : 0.00% (As of Aug. 16, 2026) - GuruFocus
Quantum BioPharma (HAM:0K91) OCF Yield % : -22.72 (As of Aug. 16, 2026) - GuruFocus
Quantum BioPharma to Host Business Update Conference Call on Tuesday, May 6, 2025 at 4:30 p.m. Eastern Time - kalkine.ca
QNTM Surges 10.5%: Quantum Biopharma Gains Momentum as It Approaches Key ResistanceIV Crush Alert - Vinanet
Quantum BioPharma Stock Surges as Lucid-MS Progress and Biotech Catalysts Fuel Bullish Momentum - kalkine.ca
Quantum Biopharma Ltd. (CN:QNTM) Shares Decline as Biotech Uncertainty, Funding Risks and Clinical Development Challenges Pressure Investor Sentiment - kalkine.ca
Quantum BioPharma Stock Faces Fresh Pressure as Biotech Risk and Funding Concerns Weigh on Sentiment - kalkine.ca
Quantum BioPharma reports Q2 results, FDA clears MS trial By Investing.com - Investing.com Nigeria
Quantum BioPharma reports Q2 results, FDA clears MS trial - Investing.com
Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial - The Manila Times
Quantum BioPharma Reports Q2 2026 Results, Reduces Operating Expenses 53% and Secures FDA Clearance for Lucid-MS Phase 2 Trial - Quiver Quantitative
Quantum BioPharma Reports Q2 2026 Results as FDA Clears Lucid-MS for Phase 2 Multiple Sclerosis Trial - kalkine.ca
Quantum BioPharma (QNTM) doubles liquidity and secures FDA clearance for Lucid-MS Phase 2 - Stock Titan
Quantum BioPharma Says Cash Could Fund Plans to Oct. 2027 - Stock Titan
Quantum Biopharma (QNTM) narrows Q2 loss but leans on crypto and new debt - Stock Titan
Quantum BioPharma Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
FDA Clears Phase 2 Trial for Demyelinating Agent Lucid-MS in Progressive Multiple Sclerosis - NeurologyLive
Quantum BioPharma (QNTM) Targets Disability Drivers Beyond Relapse Rates in Multiple Sclerosis - Yahoo Finance
Quantum BioPharma (QNTM) ties August 10 press release into Form F-3 - Stock Titan
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Targets Disability Drivers Beyond Relapse Rates in Multiple - Benzinga
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Targets Disability Drivers Beyond Relapse Rates in Multiple Sclerosis - Barchart.com
FDA Clears Quantum BioPharma's Lucid-MS for Phase 2 — QNTM Shares Slide Anyway - kalkine.ca
Quantum BioPharma Ltd. (CN:QNTM) Shares Decline as Clinical Development Risks and Biotech Market Volatility Pressure Investor Sentiment - kalkine.ca
Quantum Biopharma (QNTM) Earnings Date and Reports 2026 - MarketBeat
QUANTUM BIOPHAR (QNTM) Eps Diluted (TTM) - Zacks Investment Research
QNTM Q4 2025 Earnings: Net Loss of $0.71 Per Share, Shares Slide 1.97Analyst Earnings Estimate - Vinanet
EXCLUSIVE: Quantum BioPharma Achieves Major Milestone With FDA Clearance for Multiple Sclerosis Trial - Currently.com
Quantum BioPharma Ltd. Stock Surges 7.52% as Trading Activity Spikes and Market Attention Builds - kalkine.ca
Quantum BioPharma (QNTM) Receives FDA Clearance to Advance Lucid-MS Into Phase 2 - newmediawire.com
Quantum Biopharma Ltd. Receives United States Fda Clearance to Proceed with Lucid-Ms Phase 2 Trial in Progressive Multiple Sclerosis - marketscreener.com
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Receives FDA Clearance to Advance Lucid-MS into Phase 2 - TradingView
Quantum BioPharma Receives United States FDA Clearance To Proceed with Lucid-MS Phase 2 Trial in Progressive Multiple Sclerosis: - BNN Bloomberg
Quantum BioPharma (QNTM) Advances MS Treatment with FDA Approval Amid High Price-to-Sales Valuation - GuruFocus
FDA approves Quantum BioPharma IND for MS therapy phase 2 trial - Investing.com Nigeria
0.95%
0.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):